BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 5, 2026
Home » Authors » Shannon Ellis

Shannon Ellis

Articles

ARTICLES

Panel advises working the system to get a CFDA greenlight

May 9, 2014
By Shannon Ellis
SUZHOU, China – Navigating the obstacle course of China's regulatory system requires strategic thinking, long-term planning, creative problem solving and it doesn't hurt to have deep pockets, according to the experts discussing cross-border approvals at the Chinabio Partnering conference.
Read More

China's competitive landscape for licensing is heating up

May 7, 2014
By Shannon Ellis
SUZHOU, China – On the eve of a key biopharmaceutical partnering fest – the Chinabio Partnering Forum begins here today – BioWorld Today took a closer look at what it takes for successful dealmaking in the most populous nation on earth. The experts all agree: the landscape for licensing in China is getting more crowded with competitors.
Read More

China's competitive landscape for licensing is heating up

May 7, 2014
By Shannon Ellis
SUZHOU, China – On the eve of a key biopharmaceutical partnering fest – the Chinabio Partnering Forum begins here today – BioWorld Asia took a closer look at what it takes for successful dealmaking in the most populous nation on earth. The experts all agree: the landscape for licensing in China is getting more crowded with competitors.
Read More

Western biopharmas expected to ramp up dealmaking in China

May 7, 2014
By Shannon Ellis
SUZHOU, China – With the 6th Chinabio Partnering Forum happening this week – designed to foster cross-border partnering – the event is considered the best place for the world to meet up-and-coming Chinese life science companies. Several trends driving partnering this year promise to make the event the liveliest yet.
Read More

Western biopharmas expected to ramp up dealmaking in China

May 5, 2014
By Shannon Ellis
SUZHOU, China – With the 4th Chinabio Partnering Forum happening this week – designed to foster cross-border partnering – the event is considered the best place for the world to meet up-and-coming Chinese life science companies. Several trends driving partnering this year promise to make the event the liveliest yet.
Read More

Beijing loosens grip on drug prices; market forces to take greater role

April 30, 2014
By Shannon Ellis
SHANGHAI – Authorities in Beijing are loosening price controls for a select number of commonly used, low-cost medicines. While few innovative drugs are expected to be affected, the move signals the government is willing to take a step back when necessary in its ongoing efforts to rein in drug costs.
Read More

Alk-Abello targets China's growing allergy market, inks Eddingpharm deal

April 30, 2014
By Shannon Ellis
SHANGHAI – Alk-Abello A/S has signed a deal in which up and comer specialty pharmaceutical, Eddingpharm Co. Ltd., will handle the sales and distribution of Alk's allergy immunotherapy treatment here, products it hs been selling under its own steam since 2005.
Read More

Beijing loosens its grip on drug prices, allows market forces to take greater role

April 29, 2014
By Shannon Ellis

SHANGHAI – Authorities in Beijing are loosening price controls for a select number of commonly used, low-cost medicines. While few innovative drugs are expected to be affected, the move signals the government is willing to take a step back when necessary in its ongoing efforts to rein in drug costs.


Read More

Scouting for innovation, Sanofi urges Chinese to be more proactive

April 23, 2014
By Shannon Ellis
SHANGHAI – At the 4th Annual Biopharma China Congress in Shanghai last week, smaller biotechs and established contract research organizations (CRO) rubbed shoulders with government-funded academics. Meanwhile the China division of Sanofi SA of France was one of the only international companies in attendance.
Read More

Betta Pharma aims for initial public offering in China

April 23, 2014
By Shannon Ellis
SHANGHAI – Betta Pharmaceuticals Co. Ltd. (Betta Pharma), with the first small molecule anticancer drug in China, is aiming to go public in China later this year.
Read More
View All Articles by Shannon Ellis

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 5, 2025.
  • Art concept for medical research

    MicroRNAs in circulating extracellular vesicles as IPF biomarkers

    BioWorld Science
    MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
  • Brain illustration

    MJFF grant supports Bexorg’s translational biomarker work

    BioWorld Science
    Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
  • Brain and DNA

    REST emerges as biomarker in ALS, knockdown improves ALS symptoms

    BioWorld Science
    About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
  • Illustration of liver being targets with cross-hairs

    Study identifies CAND1 as therapeutic target in hepatoblastoma

    BioWorld Science
    Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing